Fluvoxamine and inflammation in Covid-19

This video discusses the recent confirmation that fluvoxamine is effective in decreasing the need for hospitalization in high-risk Covid-19 patients and discusses the mechanisms of action that are proposed for this effect. Fluvoxamine is discussed as an anti-inflammatory, and the inflammatory pathway that is engaged by fluvoxamine in quelling inflammation is described in some detail. Viewers are introduced to the (S1R) sigma-1 receptor and (IRE1) inositol requiring enzyme-1 inflammation pathway and the interaction of fluvoxamine with the S1R receptor and the consequent cascade is set down with diagrams showing the relationships and how these lead to a decrease in chemokines and cytokines and thus inflammation. The (IRE-1) inositol requiring enzyme 1 as a crucial chain in the inflammation pathway is demonstrated diagrammatically, making the relationships clear and easily understandable. A brief discussion of cytokine storm and the role of cytokines and chemokines in relation to the anti-inflammatory effect of fluvoxamine is also included. Viewers will gain an insight into how fluvoxamine decreases inflammation and, by so doing, learn one possible mechanism by which fluvoxamine decreases the need for hospitalization in high-risk covid-19 patients. The role of the endoplasmic reticulum is reviewed and how this relates to inflammation. Viewers are introduced to the concept of the endoplasmic reticulum and a controller of the immune response and the inflammation pathway.

Chapters

0:00 Introduction
1:25 Cytokines and chemokines
2:39 Cytokine storm
3:14 Steroids in Covid-19
3:29 Monoclonal antibodies
3:57 The argument for fluvoxamine
4:15 Brazil study
4:32 How does fluvoxamine work in Covid-19?
6:34 Conclusion